反応式
[CH3:1][C:2]1[CH:7]=[CH:6][C:5]([C:8]2[O:9][C:10]([CH3:13])=[N:11][N:12]=2)=[CH:4][C:3]=1[C:14]1[CH:19]=[CH:18][C:17]([C:20]([OH:22])=O)=[CH:16][CH:15]=1.C1C=CC2N(O)N=NC=2C=1.Cl.CN(C)CCCN=C=NCC.[CH3:45][O:46][C:47]1[CH:48]=[C:49]([CH:52]=[C:53]([O:55][CH3:56])[CH:54]=1)[CH2:50][NH2:51]>CN(C=O)C>[CH3:56][O:55][C:53]1[CH:52]=[C:49]([CH:48]=[C:47]([O:46][CH3:45])[CH:54]=1)[CH2:50][NH:51][C:20]([C:17]1[CH:16]=[CH:15][C:14]([C:3]2[CH:4]=[C:5]([C:8]3[O:9][C:10]([CH3:13])=[N:11][N:12]=3)[CH:6]=[CH:7][C:2]=2[CH3:1])=[CH:19][CH:18]=1)=[O:22]参加物
6
反応物 4
生成物 1
試薬・触媒・溶媒 1
実験手順
2′-Methyl-5′-(5-methyl-1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxylic acid (11.3 mg, 0.034 mmol), HOBT (6.0 mg, 0.044 mmol), 1-(3-dimethylaminopropyl)-3ethyl carbodiimide hydrochloride (8.0 mg, 0.042 mmol) and 3,5-dimethoxybenzylamine (0.34 mmol) were mixed in DMF (0.7 ml) and the reaction left at room temperature for 18 h. The DMF was evaporated under vacuum and the residue partitioned between DCM (0.4 ml) and water (0.4 ml). The organic phase was washed with aqueous sodium hydroxide (0.5M, 0.2 ml) and the DCM evaporated under vacuum. The residue was purified by mass directed HPLC to give N-(3,5-dimethoxybenzyl)-2′-methyl-5′-(5-methyl-1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide. LCMS; retention time 3.32 min, MH+ 444.
後処理
- customThe DMF was evaporated under vacuum
- customthe residue partitioned between DCM (0.4 ml) and water (0.4 ml)
- washThe organic phase was washed with aqueous sodium hydroxide (0.5M, 0.2 ml)
- customthe DCM evaporated under vacuum
- customThe residue was purified by mass
出典と根拠
- ORDレコード
- ord-510d7f3f199f43e4a0a26659046a04dc
- 出典データセット
- uspto-grants-2008_06
- 特許番号
- US07384963B2
関連ノート
読み込み中…